NXL Nexalin Technology, Inc.
Price Chart
Executive Summary
Nexalin announced positive results from an open-label pilot trial of its DIFS 15mA/77.5Hz neurostimulation platform in adults with generalized anxiety disorder and comorbid insomnia. The trial showed rapid, large-magnitude improvements in anxiety (77.8% response rate, HAM-A -18.30 points) and depression (66.7% response/remission), with benefits maintained at 8-week follow-up and no serious adverse events. The company is preparing a product launch in Brazil and advancing its FDA De Novo regulatory pathway, but the open-label, single-center design limits the strength of the evidence.
Actionable Insight
The strong efficacy and safety signals from this open-label pilot could drive near-term momentum, especially given the company's small market cap and prior positive clinical data. However, the open-label design and lack of a control group mean larger randomized trials are needed for FDA clearance. Watch for next steps in the HALO Clarity pivotal program and any FDA De Novo submission updates.
Key Facts
- 77.8% anxiety response rate at end of treatment (Session 20).
- HAM-A scores decreased by 18.30 points by Session 20, maintained at 8-week follow-up.
- HAMD depression scores decreased by 9.90 points by Session 20; 66.7% response and remission rates.
- PSQI insomnia scores significantly improved at end of treatment and at 8-week follow-up with large effect sizes.
- No serious adverse events, seizures, or manic/hypomanic switches reported.
- Trial was single-center, open-label, prospective pilot at University of São Paulo (20 sessions over 4 weeks + 4-week follow-up).
- Nexalin is preparing a product launch and sales campaign in Brazil and advancing FDA De Novo submission.
- Company market cap ~$9M; pre-revenue clinical-stage neurostimulation developer.
Financial Impact
No financial data in filing; company is pre-revenue. Positive clinical data supports regulatory and commercial milestones but no revenue or deal value disclosed.
Risk Factors
- Open-label, single-center design limits generalizability and may overstate efficacy due to placebo effect.
- Company is pre-revenue with ~$9M market cap; capital needs for pivotal trials and commercialization are uncertain.
- FDA De Novo pathway is not yet submitted; regulatory approval timeline and requirements are unknown.
- Competition from established neurostimulation and pharmaceutical treatments for anxiety/depression.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3309786 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 10, 2026
4d ago
|
Press Release
| $0.4443 awaiting T+5 | awaiting T+5 | — | $0.4310 (−2.99%) |
|
May 19, 2026
26d ago
|
8-K
| $0.3350 $0.5590 | ▲ +66.87% | ▲ +65.63% | $0.4310 (+28.66%) |
|
May 19, 2026
26d ago
|
Press Release
| $0.3210 $0.5063 | ▲ +57.73% | ▲ +55.48% | $0.4310 (+34.27%) |
|
Apr 22, 2026
7w ago
|
8-K
| $0.4310 $0.3470 | ▼ −19.49% | ▼ −20.97% | $0.4310 (−0.00%) |
|
Apr 22, 2026
7w ago
|
Press Release
| $0.4700 $0.3699 | ▲ +21.30% | ▲ +21.35% | $0.4310 (+8.30%) |
|
Feb 25, 2026
15w ago
|
8-K
| $0.5040 $0.4420 | ▼ −12.30% | ▼ −11.20% | $0.4310 (−14.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access